267 related articles for article (PubMed ID: 29959362)
1. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
2. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
[TBL] [Abstract][Full Text] [Related]
4. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
5. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
[TBL] [Abstract][Full Text] [Related]
6. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM
Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079
[TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
[TBL] [Abstract][Full Text] [Related]
8. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
9. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
10. LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients.
Zhang J; Zhang L; Li C; Yang C; Li L; Song S; Wu H; Liu F; Wang L; Gu J
Cell Oncol (Dordr); 2018 Feb; 41(1):73-84. PubMed ID: 29168159
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma.
Lin S; Zheng L; Lu Y; Xia Q; Zhou P; Liu Z
Cancer Med; 2020 Nov; 9(22):8624-8638. PubMed ID: 32970930
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
13. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
14. Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
Choi J; Chung T; Rhee H; Kim YJ; Jeon Y; Yoo JE; Noh S; Han DH; Park YN
Gut Liver; 2019 Jan; 13(1):83-92. PubMed ID: 29938458
[TBL] [Abstract][Full Text] [Related]
15. Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.
Ninomiya G; Yamada S; Hayashi M; Takeda S; Suenaga M; Takami H; Kanda M; Iwata N; Niwa Y; Tanaka C; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2018 Jun; 39(6):2664-2672. PubMed ID: 29620290
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of LOXL2 in pancreatic carcinoma.
Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
[TBL] [Abstract][Full Text] [Related]
17. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
18. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
[TBL] [Abstract][Full Text] [Related]
20. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
